Journal Article Review Epublish
PubMed: 40332804 DOI: 10.3390/ijms26083905
Recent Advances in Drug Development for Alzheimer's Disease: A Comprehensive Review.
Int J Mol Sci 26(8)
Authors: Haonan Xing, Song Yue, Runtian Qin, Xiaoxue Du, Yili Wu, Dongting Zhangsun, Sulan Luo
Affiliations
- Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning 530004, China.
- Key Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou Key Laboratory of Basic and Translational Research for Mental Disorders, Zhejiang Provincial Clinical Research Center for Mental Health, School of Mental Health, Institute of Aging, Wenzhou Medical University, Wenzhou 325000, China.
- Key Laboratory of Tropical Biological Resources of Ministry of Education, Hainan University, Haikou 570228, China.
- Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning 530004, China. Key Laboratory of Tropical Biological Resources of Ministry of Education, Hainan University, Haikou 570228, China.
Abstract
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by cognitive impairments such as memory loss and executive dysfunction. The primary pathological features of AD include the deposition of amyloid-beta (Aβ) plaques, the hyperphosphorylation of tau proteins leading to neurofibrillary tangles, disruptions of neuronal and synaptic functions, and chronic inflammatory responses. These multifactorial interactions drive disease progression. To date, various therapeutic agents targeting these pathological mechanisms have been developed. This article provides a comprehensive review of the pathogenesis of AD, recent advances in drug development targeting different pathways, current challenges, and future directions, aiming to offer valuable insights for clinical treatment and research.
MeSH
Drug Development, Alzheimer Disease, Pharmaceutical Preparations, Therapeutics